First reported by ft.com
AstraZeneca shares slide 9% after heart treatment disappoints in trial
FTSE 100 held back by AstraZeneca trial setback
From the article
The FTSE 100 closed down 16.59 points at 10,472.45.
Continue reading on The IndependentYou might also wanna read
FTSE 100 held back by AstraZeneca trial setback
ireland-live.ie·3h ago
AstraZeneca loses £20bn in value after major heart drug trial setback
Londonlovesbusiness·8h ago
AstraZeneca sees stock market value slump by more than £20bn after drug setback
ireland-live.ie·9h ago
London stocks mixed amid weak tech but FTSE 100 edges up
ireland-live.ie·2d ago
London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags
globalbankingandfinance.com·8h ago
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Astrazeneca's stock dropped 9.1% after disappointing Phase 3 trial results for its heart drug Wainua. Over 140 weeks, the drug failed to sta
finans.dk·10h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.